Neutrophils expressing lysyl oxidase‐like 4 protein are present in colorectal cancer liver metastases resistant to anti‐angiogenic therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutrophils expressing lysyl oxidase‐like 4 protein are present in colorectal cancer liver metastases resistant to anti‐angiogenic therapy
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-16
DOI
10.1002/path.5449
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vessel co-option in cancer
- (2019) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- Lysyl oxidase in cancer inhibition and metastasis
- (2018) Kathryn A. Johnston et al. CANCER LETTERS
- Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy
- (2018) Pieter-Jan van Dam et al. SEMINARS IN CANCER BIOLOGY
- The impact of stromal Hic-5 on the tumorigenesis of colorectal cancer through lysyl oxidase induction and stromal remodeling
- (2017) Tomokatsu Omoto et al. ONCOGENE
- Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis
- (2016) Thomas R. Cox et al. CANCER RESEARCH
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
- (2016) Sophia Frentzas et al. NATURE MEDICINE
- Neutrophils in the Tumor Microenvironment
- (2016) Davalyn R. Powell et al. TRENDS IN IMMUNOLOGY
- The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase
- (2015) Thomas R. Cox et al. NATURE
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- The morphological growth patterns of colorectal liver metastases are prognostic for overall survival
- (2014) Kåre Nielsen et al. MODERN PATHOLOGY
- Management of colorectal cancer presenting with synchronous liver metastases
- (2014) Ajith K. Siriwardena et al. Nature Reviews Clinical Oncology
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lysyl oxidase in colorectal cancer
- (2013) Thomas R. Cox et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications
- (2013) G. G. Van den Eynden et al. CANCER RESEARCH
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- The histological growth pattern of colorectal cancer liver metastases has prognostic value
- (2012) Gert G. Van den Eynden et al. CLINICAL & EXPERIMENTAL METASTASIS
- The HIF-1-Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth
- (2011) F. Pez et al. CANCER RESEARCH
- The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer
- (2011) Ann-Marie Baker et al. JNCI-Journal of the National Cancer Institute
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche
- (2009) Janine T. Erler et al. CANCER CELL
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy
- (2008) L. M. Ellis et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started